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Abstract 
Purpose: Increasing evidence exists that hyperprolactinemia alters metabolic profile. The 
mechanism of this effect is unknown. We aimed to investigate differences between metabolic 
profile of patients with prolactinomas and nonfunctional pituitary adenomas and to evaluate 
the impact of other pituitary hormones on their metabolic profile.  
Methods: Our retrospective study included 86 consecutive patients with prolactinomas and 
nonfunctional adenomas (29 prolactinomas and 57 adenomas). Body mass index (BMI), blood 
pressure, serum prolactin, growth hormone (GH), insulin-like growth factor I (IGF-I), 
adrenocorticotropic hormone (ACTH), cortisol, urinary free cortisol, triiodothyronine, 
thyroxine, thyroid-stimulating hormone (TSH), dehydroepiandrosterone-sulfate (DHEA-S), 
testosterone in men, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, 
alanine-transaminase, aspartate-transaminase, fasting glucose and C-reactive protein were 
obtained for all patients. Regression analyses were performed on log-transformed data. 
Results: After adjustment for age, gender and tumor size, prolactinomas were associated with 
higher BMI (OR 5.61, 95%CI 1.70–9.51, P=0.005), LDL cholesterol (OR 3.60, 95%CI 1.35-
5.93, P=0.015), DHEA-S (OR 1.97, 95%CI 1.23-3.72, P=0.026) and lower GH levels (OR 
0.43, 95%CI 0.03-0.84, P=0.037). In a linear multivariate regression, the association between 
DHEA-S, GH and prolactin remained significant even after adjustment for BMI. GH and IGF-
I were associated with BMI and LDL cholesterol, but the association diminished after 
adjustment for serum prolactin.  
Conclusions: Prevalence of obesity is four times higher in patients with prolactinomas than in 
patients with nonfunctional adenomas. Higher DHEA-S and lower GH levels in patients with 
prolactinomas may have an important role in prolactin-induced metabolic effects. Further 
studies are needed.      
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Introduction 
Up till recently, prolactin has been associated almost exclusively with lactation and its effects 
on sex hormones. Nowadays, prolactin is linked with a number of various functions – from its 
role in the immune system where it induces cellular and humoral immunity to the nervous 
system where it acts as a kind of neurotransmitter and has an analgesic effect [1]. Bearing in 
mind the numerous effects of physiological concentrations of prolactin, we cannot ignore 
potential complications of hyperprolactinemia other than amenorrhea-galactorrhea syndrome.  
Increasing evidence links hyperprolactinemia with insulin resistance, hyperinsulinemia, 
abnormal lipid and glucose metabolism and obesity [2-7]. Some studies associate 
hyperprolactinemia with proatherothrombotic state [8] that leads to microcirculatory disorders 
and endothelial dysfunction as the first sign of atherosclerotic events [6-8]. The majority of 
these studies were conducted on a small number of patients, and they mostly compared the 
metabolic profile and/or endothelial function before and after treatment with dopamine 
agonists. Both cabergoline and bromocriptine affect glucose metabolism regardless of the 
degree of reduction in prolactin levels [3,9]. A study by Inancli et al. showed that short-term 
treatment with cabergoline reduced body mass index (BMI), carotid intima media thickness, 
LDL cholesterol and C-reactive protein levels regardless of the decrease in prolactin levels 
[10]. Moreover, neither one study has taken into consideration the concentrations of other 
hormones of the anterior pituitary and their target glands, which may be altered in patients 
with a pituitary adenoma.  
Therefore, we aimed to investigate differences in metabolic profile between patients with 
newly diagnosed prolactinomas and nonfunctional pituitary adenomas and to evaluate the 
impact of other pituitary hormones on metabolic profile.  
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Patients and methods  
Study design 
Our retrospective study included 86 consecutive patients with newly diagnosed pituitary 
adenomas. Twenty-nine patients were diagnosed with prolactinomas and 57 with 
nonfunctional adenomas.  Prolactinomas were defined as pituitary adenomas with a diameter 
< 10 mm and serum prolactin level >70µg/L (microprolactinomas) and those with a diameter 
≥1cm and serum prolactin >100µg/L (macroprolactinomas). The remaining patients were 
diagnosed with nonfunctional pituitary adenoma. Patients who met biochemical criteria for 
Cushing's disease (normal or elevated ACTH and cortisol > 50 nmol/L in 1 mg 
dexamethasone suppression test) and acromegaly (increased IGF-I and GH > 1 ng/ml during 
oral glucose tolerance test) were excluded from the analysis. Patients that had prior pituitary 
surgery and/or were taking dopamine agonists or hormone replacement therapy were also 
excluded.  
Blood pressure and BMI were measured at admission. All patients had undergone a 
biochemical and endocrinological evaluation as well. Endocrinological evaluation included 
serum prolactin, growth hormone (GH), insulin like growht factor-1 (IGF-I), 
adrenocorticotropic hormone (ACTH), morning cortisol, urinary free cortisol, 
dehydroepiandrosterone-sulfate (DHEA-S), triiodothyronine (T3), thyroxine (T4), thyroid-
stimulating hormone (TSH) and testosterone in men.  Biochemical parameters included 
triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, alanine transaminase 
(ALT), aspartate transaminase (AST), fasting blood glucose and C-reactive protein (CRP).  
Patients were defined as overweight if their body mass index (BMI) was 25-30 kg/m
2
 and as 
obese if BMI > 30 kg/m
2
. Hypercholesterolemia was diagnosed in patients with LDL > 3,0 
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mmol/L, hypertriglyceridemia in patients with triglycerides > 1.7 mmol/L, diabetes in patients 
with fasting glucose >7.0 mmol/L.  
 
Radiological evaluation 
Magnetic resonance imaging (MRI) was performed in all patients using a 1.5 Tesla MRI 
according to the standard protocol. It included T1 and T2 - weighted sequences and dynamic 
T1 - weighted imaging after gadolinium-base contrast medium. 
 
Laboratory methods 
Quantitative measurements of TSH, T4, T3, IGF-1 and GH were made with CLIA - 
chemiluminescent immuno assay on the Imulite-1000 by Siemens. The normal ranges of their 
concentrations are as follow: TSH 0.4-4.0 mIJ/L, T4 60-165 nmol/L, T3 1.1-2.8 nmol/L, IGF-
I 115-420 ng/mL, a GH 0-5 ng/mL. Quantitative measurements of cortisol, ACTH, DHEA-S 
and testosterone were made with ECLIA - electrochemiluminescent immuno assay on the 
autoanalizer Cobase 411 by Roche Diagnostics Gmbh. The normal range of their 
concentrations are as follow: morning cortisol  138 – 800 nmol/L, ACTH <10.1 pmol/L, 
DHEA-S 2.45 - 12.1 nmol/L and testosterone 10.5- 22.5 nmol/L . Urinary free cortisol was 
measured with ELISA – enzyme-linked immunosorbent assay with chemicals of the DRG 
Diagnostics Gmbh Company, with the normal concentration being between 54 and 319 
nmol/24h. Quantitative measurement of prolactin was made with the DELFIA fluorescent 
method by the PerkinElmer Company. Normal range for women: 2.0 – 30.0 μg/L and for 
men: 2.0 – 20.0 μg/L.  
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Routine biochemical serum analyses (HDL, LDL, total cholesterol, triglycerides, AST, ALT, 
fasting blood glucose and CRP) were made with original chemicals (Beckman Coulter 
International S. A.) for all parameters. All analyses were made with the analytic system on the 
automatic analyzer AU 2700 (Beckman 40). The normal range of their concentrations are as 
follow: HDL for women >1.2mmol/l, HDL for men >1.0mmol/L, LDL 0-3mmol/L, total  
cholesterol for adults <5.0mmol/L, triglycerides 0-1.7mmol/L, AST for men 11-38 U/L, AST 
for women 8-30 U/L, ALT for men 12-48 U/L, ALT for women 10-36 U/L, fasting blood 
glucose 4.4-6.4 mmol/L, CRP <5.0 mg/L. 
 
Statistical analyses  
Patient characteristics were assessed using descriptive statistics presented as a median with 
interquartile range values. Independent continuous variables were compared using Mann-
Whitney test and categorical variables were compared using Fisher's exact test. The majority 
of parameters did not follow normal distribution and therefore all continous variables were 
transformed by logarithm to base 10. Afterwards, we used two approaches to analyze the 
association between prolactin and other parameters. Firstly, we compared two groups by 
using binary logistic regression. Logistic regression was also used to adjust for age, gender, 
tumor size and other confounding factors. Secondly, we aimed to analyze the correlation 
between serum prolactin levels and other parameters in all patients, regardless of the tumor 
type. Spearman correlation was used to assess the association between prolactin and other 
variables. Linear regression was used to adjust other confounding factors. Our power analysis 
demonstrated a power of 88% for the lowest correlation coefficient (GH) and a power of 99% 
for the highest correlation coefficient (DHEA-S).  Software SPSS 20.0 for Windows was used 
to perform all the analyses. P value <0.05 was considered significant. 
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Results 
Patients characteristics  
Patients had a median age of 33.0 years (27.0-41.0) and had a median tumor size of 9 mm (6-
14.5). More female patients were diagnosed with nonfunctional adenomas (P=0.016). Patients 
with prolactinomas presented with larger tumors (P=0.017), but there was no difference in age 
between the groups. Two patients with prolactinomas and one patient with nonfunctional 
adenoma were taking statins, 7 patients with nonfunctional adenomas and 7 patients with 
prolactinomas were taking antihypertensive agents one patient with nonfunctional adenoma 
was taking metformin. Prevalence of obesity and hypercholesterolemia was higher in patients 
with prolactinomas (Table 1). Biochemical and endocrinological evaluation showed that 
patients with prolactinomas had higher total cholesterol, LDL cholesterol, CRP, DHEA-S and 
ACTH levels, but lower IGF-I and GH (Table 2). There were no significant differences in 
other parameters.   
 
Regression analysis between patients with prolactinomas and nonfunctional adenomas 
Logistic regression was performed in order to closely examine these associations and to adjust 
for of other varables. Patients with prolactinomas had 4-fold higher risk for obesity (relative 
risk 3.93, 95%CI 1.92 – 8.05). Accordingly, univariate analysis confirmed that patients with 
prolactinomas had significantly higher BMI. This positive correlation remained significant 
after adjustment for age, gender and tumor size (OR 5.61, 95%CI 1.70 – 9.51, P = 0.005). 
Binary logistic regression confirmed that patients with prolactinomas had higher total 
cholesterol (OR 1.99, 95% CI 1.09-3.65, P = 0.016) and LDL (OR 2.83, 95% CI 1.35 - 5.93, 
P = 0.002). After adjustment for age, gender and tumor size, the difference in total cholesterol 
was not significant (P = 0.088), but for LDL the difference was still evident (OR 3.60, 95% 
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CI 1.35-5.93, P = 0.015). However, the association between LDL and prolactinomas 
diminished after adjustment for BMI. The association between prolactinomas and CRP was 
significant in univariate binary logistic regression, but diminished after adjustment for age and 
gender. Although patients with prolactinomas had significantly higher CRP and ACTH 
(Mann-Whitney test), we found no significant correlations after univariate nor multivariate 
analysis.  
After adjustment for age, gender and tumor size, patients with prolactinomas had lower GH 
(OR 0.43, 95%CI 0.03 - 0.84, P=0.037). However, after adjustment for BMI this association 
was no longer statistically significant. Patients with prolactinomas did have significantly 
lower age-adjusted IGF-I, but the association diminished after adjustment for gender, and 
remained insignificant in multivariate model with the rest of variables. 
Positive association of DHEA-S and prolactinomas was confirmed in binary logistic 
regression and remained significant after adjustment for age, gender and tumor size (OR 1.97, 
95% CI 1.23-3.72, P = 0.026). However, after including BMI into a multivariate model, this 
association became insignificant.  
 
Correlation of prolactin levels and variables within the study population 
Serum prolactin correlated inversely with T4, IGF-I and GH and positively with BMI, 
DHEAS, LDL and CRP. The association remained significant only for BMI, GH and DHEA-
S after adjustment for age, gender and tumor size (Table 3). In a subgroup analysis of male 
patients, we found negative correlation between prolactin and testosterone (ρ = -0.479) but it 
did not reach statistical significance (P = 0.07). On the other hand, we observed strong 
negative correlation between DHEA-S and prolactin (ρ = 0.721, P = 0.019). There was no 
significant correlation between testosterone and DHEA-S. 
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DHEA-S correlated positively with CRP, but this correlation diminished after adjustment for 
serum prolactin. We found no correlation between serum DHEA-S and BMI or LDL 
cholesterol. On the other hand, both serum IGF-I and GH were inversely associated with 
BMI, CRP, LDL and triglycerides, but positively associated with HDL cholesterol. After 
adjustment for serum prolactin, only positive correlation between GH and HDL cholesterol (r 
= 0.315, P = 0.04) and negative correlation between IGF-I and CRP (r = -0.356, P = 0.019), 
LDL (r = -0.366, P = 0.031) remained significant.      
     
Discussion 
Prolactinomas represent 40% of all pituitary tumors. They are classified according to their 
size as macroprolactinomas (≥10 mm) or microprolactinomas (<10 mm). Patients are 
diagnosed with prolactinomas if they harbor macroadenoma with prolactin levels > 100 µg/L 
/L, or microadenoma with increased prolactin levels. Typically, young females with 
microadenomas represent the vast majority of patients with prolactinomas [11]. In our study, 
young females were mostly diagnosed with nonfunctional adenoma since we used a prolactin 
> 70 mcg/L cutoff to diagnose patients with prolactinomas [11]. This was necessary in order 
to insure that all patients in prolactinoma group really do have primary hyperprolactinemia. 
This is rather important, since approximately 64% of patients with polycystic ovary syndrome 
have secondary hyperprolactinemia and often have nonfunctional microadenomas, 
misdiagnosed as microprolactinomas [12]. However, due to atypical diagnostic criteria for 
prolactinomas, linear regression models were conducted on the entire study population 
regardless of the prolactin cut-off value used for the diagnosis of prolactinoma. We obtained 
similar results after conducting two different approaches of statistical analyses. This brings 
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additional power to our conclusions and reduces the possibility of a bias due to criteria used 
for the diagnosis of prolactinomas.          
Our study showed that patients with prolactinomas have higher BMI and LDL levels than 
patients with nonfunctional pituitary adenomas. This observation is in accordance with 
previous studies that reported a decrease in BMI and total cholesterol after treatment with 
dopamine agonists [2,3,10,13]. However, our study is the first to report that patients with 
prolactinomas have higher BMI and LDL cholesterol, independently of dopamine agonists. 
This is important since dopamine agonists may affect metabolic profile regardless of the 
degree of reduction in prolactin levels [3,9,10]. Additional new information is that 
hypercholesterolemia is simply the consequence of obesity, rather than directly associated 
with hyperprolactinemia. This can be concluded from the fact that the association between 
hypercholesterolemia and hyperprolactinemia was lost after adjustment for BMI.  Previous 
studies have also emphasized the role of insulin resistance in alteration of metabolic profile in 
patients with hyperprolactinemia. However, patients with hyperprolactinemia in those studies 
had baseline HOMA-IR of only 1.5, which could hardly be defined as insulin resistance [3]. 
Some evidence exists that morbidly obese subjects have low levels of serum prolactin [14], 
along with the strong negative correlation between prolactin and insulin resistance [14]. 
Hence, it is highly unlikely that insulin resistance could explain hyperprolactinemia-induced 
alterations in metabolic profile. Unfortunately, since this is a retrospective study, we can’t 
provide information on insulin resistance in our patients. However, there was a trend of lower 
fasting glucose levels and lower prevalence of diabetes in patients with prolactinomas. 
Despite the limitations, our study suggests that higher levels of DHEA-S and lower GH levels 
may explain the metabolic effects associated with hyperprolactinemia. 
Few small and clearly forgotten studies published three decades ago, reported that patients 
with hyperprolactinemia have higher levels of DHEA-S [15-17]. Using monolayer cultures of 
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human adrenal cells, the authors showed direct stimulatory effect of prolactin on DHEA and 
DHEA-S secretion [16]. Unfortunately, these studies haven’t analyzed the metabolic profile 
of patients and therefore could not elucidate the true impact of DHEA-S. However, previous 
epidemiological studies on healthy individuals, reported positive correlation between DHEA-
S and BMI, LDL cholesterol and cardiovascular risk [18]. Additionally, DHEA-S had no 
effect on insulin resistance [19]. Patients with prolactinomas in our study had higher levels of 
DHEA-S, BMI and LDL cholesterol. Moreover, there was a strong positive correlation 
between serum prolactin level and BMI, but also between serum prolactin and DHEA-S. The 
correlation between prolactin and DHEA-S was not influenced by BMI, which suggests that 
prolactin directly stimulates DHEA-S secretion. Similar inverse association was found for GH 
and prolactin. Although obese individuals tend to have lower GH and IGF-I levels due to 
hyperinsulinemia, the correlation between prolactin and GH remained significant even after 
adjustment for BMI. We found no significant correlations between the DHEA-S and 
metabolic syndrome components. However, this is a subgroup analysis and the conclusions 
must be drawn carefully, since the sample size may not be sufficient to detect those 
associations, which were clearly evident in previously mentioned studies. But on the other 
hand, GH and IGF-I were associated with BMI and several other components of metabolic 
syndrome. The majority of these associations diminished after adjustment for prolactin levels, 
indicating that GH effects may be mediated by hyperprolactinemia.  To our knowledge, 
neither one study has previously found similar association between GH and prolactin. Bearing 
in mind the common embryological origin of lactotropic and somatotropic cells, we suggest 
that there is a possibility that chronic hyperprolactinemia may suppress GH secretion. On the 
other hand, there is some evidence that IGF-1 gene therapy reverses morphological changes 
and reduces hyperprolactinemia in rats with prolactinomas [20].  
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In conclusion, patients with prolactinomas have higher BMI, LDL cholesterol, DHEA-S and 
lower GH levels than patients with nonfunctional adenomas. The association between 
hypercholesterolemia and hyperprolactinemia was lost after adjustment for BMI, which 
suggests that hypercholesterolemia is simply the consequence of obesity, rather than directly 
associated with hyperprolactinemia. We found strong positive correlation between prolactin 
and DHEA-S and negative correlation between serum prolactin and GH, which was 
independent of BMI. We found no correlation between DHEA-S and BMI, but GH and IGF-I 
were associated with obesity and several components of metabolic syndrome. Interestingly, 
these associations diminished after adjustment for prolactin levels, indicating that GH effects 
are mediated by hyperprolactinemia. Higher DHEA-S and lower GH levels in patients with 
prolactinomas may have an important role in prolactin-induced metabolic effects. Further 
studies in this field are needed.      
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Table 1. Anthropometric parameters of the study population divided based on tumor type 
  
Prolactinoma 
N=29 
Nonfunctional adenoma  
N=57 
P value 
Gender  
  
  
Male No (%) 10 (34%) 6 (11%) 0.016 
Age (years) 34.0 (29.5-49.8) 32.0 (26.8-40.0) 0.246 
Tumor size (cm) 1.0 (0.7-2.0) 0.8 (0.5-1.3) 0.017 
BMI (kg/m
2
) 31.0 (24.6-34.6) 21.5 (19.9-23.9) <0.001 
Systolic pressure (mmHg) 125 (120-140) 120 (110-130) 0.087 
Diastolic pressure (mmHg) 80 (70-85) 80 (75-90) >0.3 
Overweight No (%) 4 (13.8) 10 (17.5) >0.3 
Obesety No (%) 17 (59) 10 (17.5) <0.001 
Diabetes No (%) 0 (0) 7 (12.3) 0.090 
Hypercholesterolemia No (%) 25 (86.2) 22 (38.6) <0.001 
Hypertryglyceridemia No (%) 12 (41.4) 15 (26.3) 0.220 
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Table 2. Biochemical parameters of the study population divided based on tumor type 
 
Prolactinoma 
N=29 
Nonfunctional adenoma 
N=57 
P value 
LDL (mmol/L) 3.90 (3.43-4.33) 2.75 (2.30-3.78) 0.004 
HDL (mmol/L) 1.28 (1.07-1.49) 1.21 (1.03-1.50) >0.3 
Total cholesterol (mmol/L) 5.94 (5.08-6.42) 4.65 (4.24-5.52) 0.005 
Triglycerides (mmol/L) 1.66 (0.94-2.03) 1.21 (0.97-1.53) 0.184 
AST (U/L) 17.0 (11.8-23.0) 17.0 (12.0-22.0) >0.3 
ALT (U/L) 18.0 (15.0-23.3) 20.0 (16.5-23.0) >0.3 
Glucose (mmol/L) 5.1 (4.7-5.5) 4.9 (4.6-5.4) >0.3 
CRP (mg/L) 2.1 (1.1-6.1) 0.8 (0.5-2.1) 0.002 
Prolactin (μg/L) 148.6 (103.8-625.5) 22.7 (10.7-51.4) <0.001 
Cortisol (nmol/L) 487.0 (346.8-552.5) 458.0 (317.0-557.5) >0.3 
ACTH (pmol/L) 8.92 (6.64-9.86) 6.65 (4.01-9.24) 0.035 
DHEA-S (nmol/L) 7.58 (5.32-8.91) 4.43 (2.17-7.06) 0.039 
Urinary cortisol (nmol/24h) 120.5 (90.0-244.0) 148.0 (98.0-223.0) 0.300 
T4 (nmol/L) 90.2 (74.2-105.3) 94.4 (80.2-106.5) >0.3 
T3 (nmol/L) 1.6 (1.3-1.8) 1.6 (1.3-1.8) >0.3 
TSH (mIU/L) 2.33 (1.51-2.88) 1.98 (1.17-2.71) 0.235 
Testosterone in men (nmol/L) 5.1 (1.1-7.4) 7.2 (5.05-15.8) 0.175 
Growth hormone (ng/ml) 0.14 (0.06-0.40) 0.32 (0.11-0.92) 0.021 
IGF-I (ng/ml) 157.0 (127.5-201.0) 193.0 (150.5-254.5) 0.020 
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Table 3. Correlation coefficients and p values showing the association between serum 
prolactin and other parameters.  
 
     BMI       T4     IGF-I      GH DHEA-S     CRP     LDL 
Unadjusted (ρ) .394 
 
-.322 -.309 -.296 .489 .328 .324 
P value .005 .005 .015 .015 .002 .008 .034 
Adjusted for age (r) 0.477 
 
-.341 -.357 -.298 .619 .266 .357 
P value .002 .003 .012 .014 .000 .037 .031 
Adjusted for age and 
gender (r) 
.385 -.221 -.277 -.256 .487 .176 .295 
P value .013 .046 .034 .022 .001 .172 .045 
Multivariable model 
including tumor size
a 
(r) 
.327 -.154 -.230 -.273 .522 .161 .221 
P value .046 0.200 .086 .017 .001 .191 .152 
Multivariable model 
including BMI
b 
(r)
 
NA -.050 -.261 -.347 .600 .172 .074 
P value NA >.3 .102 .015 .002 >.3 >.3 
a 
multivariable model including age, gender and tumor size, 
b
 multivariable model including age, 
gender, tumor size and BMI; NA – not analyzed 
 
 
 
 
 
